New Burixafor Clinical Data to be Presented as an Oral Presentation at the 2025 ASH Annual Meeting
Exicure (Nasdaq: XCUR) announced that completed Phase 2 data for burixafor, a CXCR4 antagonist, will be presented orally at the 67th ASH Annual Meeting on December 8, 2025. The oral presentation (Abstract 1050) reports results from an open-label, multicenter Phase 2 trial (NCT05561751) of burixafor plus G-CSF and propranolol to mobilize hematopoietic progenitor cells in multiple myeloma patients undergoing autologous hematopoietic cell transplantation.
The presentation highlights an excellent safety profile, same-day administration with leukapheresis, and that 18 of 19 patients who chose transplant proceeded to AHCT; many enrolled patients had prior daratumumab exposure. Presenter: Dr. Jack Khouri. Session: Cell Collection and Manufacturing; 5:45–6:00pm EST, Hyatt Regency Ballroom R.
Exicure (Nasdaq: XCUR) ha annunciato che i dati di fase 2 completati per burixafor, antagonista CXCR4, saranno presentati oralmente al 67° Annual Meeting dell'ASH il 8 dicembre 2025. La presentazione orale (Abstract 1050) riporta i risultati di uno studio multicentrico di fase 2, aperto (NCT05561751) di burixafor più G-CSF e propranololo per mobilizzare le cellule progenitrici ematopoietiche in pazienti con mieloma multiplo sottoposti a trapianto autologo di cellule staminali ematopoietiche.
La presentazione evidenzia un profilo di sicurezza eccellente, somministrazione nello stesso giorno dell'affferenesi (leukapheresi), e che 18 su 19 pazienti che hanno scelto il trapianto sono passati al AHCT; molti pazienti arruolati avevano esposto in precedenza a daratumumab. Relatore: Dr. Jack Khouri. Sessione: Raccolta e Produzione di cellule; 17:45–18:00 EST, Hyatt Regency Ballroom R.
Exicure (Nasdaq: XCUR) anunció que los datos de fase 2 completados para burixafor, un antagonista de CXCR4, se presentarán oralmente en la 67.ª Reunión Anual de ASH el 8 de diciembre de 2025. La presentación oral (Resumen 1050) reporta los resultados de un ensayo multicéntrico, abierto, de fase 2 (NCT05561751) de burixafor más G-CSF y propranolol para movilizar células progenitoras hematopoyéticas en pacientes con mieloma múltiple sometidos a trasplante autólogo de células hematopoyéticas.
La presentación destaca un perfil de seguridad excelente, administración el mismo día de la aféresis, y que 18 de 19 pacientes que optaron por el trasplante pasaron al AHCT; muchos pacientes inscritos habían tenido exposición previa a daratumumab. Presentador: Dr. Jack Khouri. Sesión: Recolección y Manufactura de células; 5:45–6:00 p.m. EST, Hyatt Regency Ballroom R.
Exicure (나스닥: XCUR)가 CXCR4 길항제인 burixafor의 2상 완료 데이터를 제67회 ASH 연례회의에서 2025년 12월 8일에 구두 발표할 것이라고 발표했습니다. 구두 발표(Abstract 1050)는 다기관 비밀개방형(open-label) 2상 시험(NCT05561751)에서 burixafor + G-CSF 및 propranolol을 이용해 자가 혈액조혈모세포 이식을 받는 다발성 골수종 환자들의 조혈모세포를 동원하기 위한 연구의 결과를 보고합니다.
발표는 우수한 안전성 프로필, 동일 날의 백혈구 여과( Leukapheresis ) 투여, 그리고 18명 중 19명의 이식 선택 환자들이 AHCT로 진행했다는 점을 강조합니다. 다수의 등록 환자들이 다라투무맙에 사전 노출이 있었습니다. 발표자: Dr. Jack Khouri. 세션: 세포 수집 및 제조; EST 17:45–18:00, Hyatt Regency Ballroom R.
Exicure (Nasdaq: XCUR) a annoncé que les données de phase 2 complètes pour burixafor, un antagoniste du CXCR4, seront présentées oralement lors de la 67e Réunion annuelle de l'ASH le 8 décembre 2025. La présentation orale (Résumé 1050) rapporte les résultats d'un essai multicentrique en phase 2, ouvert (NCT05561751) de burixafor plus G-CSF et propranolol pour mobiliser les cellules souches hématopoïétiques chez des patients atteints de myélome multiple subissant une transplantation autologue de cellules souches hématopoïétiques.
La présentation met en évidence un profil de sécurité excellent, une administration le jour même que l’apherèse et que 18 sur 19 patients ayant choisi la transplantation sont passés à l’AHCT; de nombreux patients inclus avaient été exposés préalablement au daratumumab. Présentateur : Dr. Jack Khouri. Session: Collecte et fabrication de cellules; 17h45–18h00 EST, Hyatt Regency Ballroom R.
Exicure (Nasdaq: XCUR) gab bekannt, dass die abgeschlossenen Phase-2-Daten zu burixafor, einem CXCR4-Antagonisten, am 67. Jahrestreffen der ASH am 8. Dezember 2025 mündlich vorgestellt werden. Die mündliche Präsentation (Abstract 1050) berichtet von den Ergebnissen einer offenen, multizentrischen Phase-2-Studie (NCT05561751) von Burixafor plus G-CSF und Propranolol zur Mobilisierung hämatopoetischer Vorläuferzellen bei Patienten mit multiples Myelom, die sich einer autologen Transplantation von Blutstammzellen unterziehen.
Die Präsentation hebt ein ausgezeichnetes Sicherheitsprofil, die gleiche Tag der Leukapherese und die Tatsache hervor, dass 18 von 19 Patienten, die sich für eine Transplantation entschieden hatten, zur AHCT überzogen; viele eingeschlossene Patienten hatten zuvor Daratumumab erhalten. Referent: Dr. Jack Khouri. Sitzung: Zellensammlung und -herstellung; 17:45–18:00 EST, Hyatt Regency Ballroom R.
Exicure (نوتسداك: XCUR) أعلنت أن بيانات المرحلة 2 المكتملة لـ burixafor، وهو مضاد CXCR4، سيُعرض شفويًا في المؤتمر السنوي السابع والستين لـ ASH في 8 ديسمبر 2025. العرض الشفوي (الملخص 1050) يورد نتائج تجربة موالاة مفتوحة متعددة المراكز من المرحلة 2 لـ burixafor مع G-CSF وPropranolol من أجل تحريك الخلايا المنشئة الدمويّة في مرضى الورم المتعدد الذين يخضعون لزرع الخلايا الجذعية الدمويّة الذاتية.
تؤكد العرض على ملف أمان ممتاز، وإعطاء في نفس يوم عزل الدم، وأن 18 من أصل 19 مريضًا اختاروا الزرع واستمروا إلى AHCT؛ كثير من المرضى المسجلين كانت لديهم تعرض سابق لـ daratumumab. المقدم: الدكتور جك Khouri. الجلسة: جمع الخلايا وتصنيعها؛ 5:45–6:00 م بتوقيت شرق الولايات المتحدة، صالة هايويت ريجينسي بال روم R.
- None.
- None.
Insights
Phase 2 burixafor data to be presented at
Exicure reports an oral presentation at the 67th ASH meeting of Phase 2 results for burixafor (a CXCR4 antagonist) combined with G-CSF and propranolol. The mechanism is clear: CXCR4 blockade mobilizes hematopoietic progenitor cells into peripheral blood for collection and subsequent AHCT. The study was open-label and multicenter and targeted multiple myeloma patients undergoing autologous hematopoietic cell transplantation.
Reported outcomes show an excellent safety profile and that all patients who elected transplant (18/19) proceeded to AHCT, despite most participants having prior exposure to daratumumab. This detail matters because daratumumab has been linked to reduced mobilization in some reports; the presented result suggests the combination achieved adequate mobilization in this cohort. The same-day administration with leukapheresis may improve patient convenience and reduce time burden.
Dependencies and risks include the open-label design, limited sample size implied by the 18/19 figure, and lack of presented quantitative mobilization metrics or comparator arms in this summary. Watch for the full abstract (No. 1050) presented on
REDWOOD CITY, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced that results from its completed Phase 2 study evaluating burixafor, a small molecule CXCR4 antagonist, will be featured in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 6-9, 2025, in Orlando, Florida.
The presentation will highlight additional patient data from the open-label, multicenter Phase 2 trial (NCT05561751) assessing burixafor in patients with multiple myeloma undergoing autologous hematopoietic cell transplantation (AHCT). By blocking CXCR4, burixafor is designed to mobilize hematopoietic progenitor cells from the bone marrow into the peripheral blood, where they can be collected for use in transplantation procedures.
“The combination of burixafor, G-CSF and propranolol demonstrated an excellent safety profile and was able to ensure adequate and efficient mobilization of hematopoietic progenitor cells, with all patients who chose to undergo transplant (18/19) proceeding to AHCT. These are very encouraging results, especially since the majority of the enrolled patients were treated with the anti-CD38 monoclonal antibody daratumumab, which has been associated with lower HPC mobilization in certain studies. The same day administration of burixafor with leukapheresis is also more convenient for patients and may reduce time toxicity,” said Jack Khouri, M.D., Associate Professor of Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, study lead investigator, and presenter.
Oral Presentation Details
Abstract Number: 1050
Title: An open-label, multi-center Phase 2 study to assess the safety and efficacy of burixafor (GPC-100) and propranolol with G-CSF for the mobilization of hematopoietic progenitor cells in patients with multiple myeloma
Presenter: Dr. Jack Khouri, Associate Professor of Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University
Session: 711. Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products: Refining CAR-T Cells and Engineered HSPCs; New Approaches to HSPC mobilization
Date and Time: December 8, 2025, 5:45-6:00pm EST
Location: Hyatt - Regency Ballroom R
About Burixafor (GPC-100)
Burixafor (GPC-100) is a highly selective small molecule antagonist of CXCR4, a chemokine receptor that plays a central role in retaining hematopoietic stem cells in the bone marrow niche. By blocking CXCR4, burixafor may enhance the mobilization of these cells into the peripheral blood for collection and use in autologous stem cell transplant (ASCT) procedures. Originally developed by GPCR Therapeutics, Inc., burixafor became part of Exicure’s pipeline following the company’s acquisition in January 2025. In addition to multiple myeloma, burixafor is also being considered in other diseases where improved stem cell mobilization could help enable more efficient and effective treatment approaches, such as sickle cell disease, rare diseases requiring autologous transplant, and cell and gene therapy settings. A chemosensitization trial in AML is also being planned, leveraging burixafor’s mechanism of mobilizing malignant cells from protective bone marrow niches into the peripheral blood, where they may be more effectively targeted by chemotherapy.
About Exicure
Exicure, Inc. (Nasdaq: XCUR) is a clinical-stage biotechnology company developing therapies to address key challenges in hematologic diseases. The company’s lead program, burixafor (GPC-100), is being evaluated for its ability to improve stem cell mobilization in multiple myeloma, sickle cell disease, and in support of cell and gene therapy. It is also being studied as a potential chemosensitizing agent in acute myeloid leukemia (AML). For more information, visit www.exicuretx.com.
Contact:
Exicure, Inc.
847.673.1700 (Tel)
847.556.6411 (Fax)
FAQ
When and where will Exicure present burixafor Phase 2 data at ASH 2025 (XCUR)?
What Phase 2 trial results for burixafor (XCUR) will be reported at ASH 2025?
Who will present Exicure's burixafor data at ASH 2025 and what is the abstract number?
What treatment combination was studied with burixafor in the Phase 2 trial (XCUR)?
How did prior daratumumab exposure factor into the burixafor Phase 2 results for XCUR?
